186 related articles for article (PubMed ID: 15667873)
21. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
Scales CD; Presti JC; Kane CJ; Terris MK; Aronson WJ; Amling CL; Freedland SJ;
J Urol; 2007 Oct; 178(4 Pt 1):1249-52. PubMed ID: 17698131
[TBL] [Abstract][Full Text] [Related]
22. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
Jayadevappa R; Chhatre S; Whittington R; Bloom BS; Wein AJ; Malkowicz SB
BJU Int; 2006 May; 97(5):955-62. PubMed ID: 16643477
[TBL] [Abstract][Full Text] [Related]
23. Impact of patient age on biochemical recurrence rates following radical prostatectomy.
Magheli A; Rais-Bahrami S; Humphreys EB; Peck HJ; Trock BJ; Gonzalgo ML
J Urol; 2007 Nov; 178(5):1933-7; discussion 1937-8. PubMed ID: 17868723
[TBL] [Abstract][Full Text] [Related]
24. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
25. Impact of salvage therapy for biochemical recurrence on health-related quality of life following radical prostatectomy.
Namiki S; Saito S; Tochigi T; Ioritani N; Terai A; Arai Y
Int J Urol; 2007 Mar; 14(3):186-91. PubMed ID: 17430252
[TBL] [Abstract][Full Text] [Related]
26. Pre-operative percent free PSA predicts clinical outcomes in patients treated with radical prostatectomy with total PSA levels below 10 ng/ml.
Shariat SF; Abdel-Aziz KF; Roehrborn CG; Lotan Y
Eur Urol; 2006 Feb; 49(2):293-302. PubMed ID: 16387412
[TBL] [Abstract][Full Text] [Related]
27. Perineural invasion affects biochemical recurrence-free survival in patients with prostate cancer treated with definitive external beam radiotherapy.
Yu HH; Song DY; Tsai YY; Thompson T; Frassica DA; DeWeese TL
Urology; 2007 Jul; 70(1):111-6. PubMed ID: 17656219
[TBL] [Abstract][Full Text] [Related]
28. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus.
Levinson A; Nagler EA; Lowe FC
Urology; 2005 Jan; 65(1):91-4. PubMed ID: 15667871
[TBL] [Abstract][Full Text] [Related]
29. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
30. External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer.
Zhigang Z; Wenlu S
Prostate; 2007 May; 67(6):653-60. PubMed ID: 17342746
[TBL] [Abstract][Full Text] [Related]
31. Partnership and outcomes in men with prostate cancer.
Bergman J; Gore JL; Saigal CS; Kwan L; Litwin MS
Cancer; 2009 Oct; 115(20):4688-94. PubMed ID: 19626653
[TBL] [Abstract][Full Text] [Related]
32. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
33. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure.
Ray ME; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Zelefsky MJ; Zietman AL; Kuban DA
Urology; 2006 Dec; 68(6):1257-62. PubMed ID: 17141830
[TBL] [Abstract][Full Text] [Related]
34. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance.
Latini DM; Hart SL; Knight SJ; Cowan JE; Ross PL; Duchane J; Carroll PR;
J Urol; 2007 Sep; 178(3 Pt 1):826-31; discussion 831-2. PubMed ID: 17632144
[TBL] [Abstract][Full Text] [Related]
35. Disease-specific quality of life among patients with localized prostate cancer: an Australian perspective.
Newton FJ; Burney S; Millar JL; Frydenberg M; Ng KT
BJU Int; 2006 Jun; 97(6):1179-83. PubMed ID: 16686708
[TBL] [Abstract][Full Text] [Related]
36. Radical prostatectomy for clinical stage T3a disease.
Freedland SJ; Partin AW; Humphreys EB; Mangold LA; Walsh PC
Cancer; 2007 Apr; 109(7):1273-8. PubMed ID: 17315165
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
Soga N; Onishi T; Arima K; Sugimura Y
Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
[TBL] [Abstract][Full Text] [Related]
38. Quality of life for men receiving a second treatment for prostate cancer.
Arredondo SA; Latini DM; Sadetsky N; Kawakami J; Pasta DJ; DuChane J; Carroll PR;
J Urol; 2007 Jan; 177(1):273-8; discussion 278-9. PubMed ID: 17162062
[TBL] [Abstract][Full Text] [Related]
39. Five-year follow-up of health-related quality of life after intensity-modulated radiation therapy for prostate cancer.
Namiki S; Ishidoya S; Ito A; Tochigi T; Numata I; Narazaki K; Yamada S; Takai Y; Arai Y
Jpn J Clin Oncol; 2009 Nov; 39(11):732-8. PubMed ID: 19666904
[TBL] [Abstract][Full Text] [Related]
40. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
